A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma

NCT02178358 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

132

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: LY2157299
DRUG: Sorafenib
DRUG: Placebo

Sponsor

Eli Lilly and Company